Skip to main content
SpringerLink
Log in

Chemotherapy and Chemoradiotherapy

  • Chapter
  • First Online:
Esophageal Squamous Cell Carcinoma

  • 436 Accesses

Abstract

There are various roles of chemotherapy and chemoradiotherapy for the treatment of esophageal squamous cell carcinoma (ESCC). Cytotoxic agents were used as palliative chemotherapy for metastatic or recurrent cases, which consist 5-FU and platinum agents mostly. For failure following the first-line chemotherapy, taxanes are used as the second-line chemotherapy of ESCC. Recently triplet combination with 5-FU, platinum, and taxanes has been evaluated in the first-line chemotherapy. As for chemoradiotherapy, the schedule and dose of radiation, and timing of salvage treatment has been optimized. In earlier line, comparable efficacy of chemoradiotherapy was reported compared to surgery. Immune-checkpoint inhibitor (ICI) showed impact on the survival of patients who failed to the first-line chemotherapy in comparison with chemotherapy. ICI has also been evaluated as first-line chemotherapy, combination with chemoradiotherapy, pre- and postoperative therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tancini G, Bajetta E, Bonadonna G. Bleomycin alone and in combination with methotrexate in the treatment of carcinoma of the esophagus. Tumori. 1974;60:65–71.

    Article  CAS  PubMed  Google Scholar 

  2. Bonadonna G, De Lena M, Monfardini S, et al. Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer. 1972;8:205–15.

    Article  CAS  PubMed  Google Scholar 

  3. Ravry M, Moertel CG, Schutt AJ, et al. Treatment of advanced squamous cell carcinoma of the gastrointestinal tract with bleomycin (NSC-125066). Cancer Chemother Rep. 1973;57:493–5.

    CAS  PubMed  Google Scholar 

  4. Ezdinli EZ, Gelber R, Desai DV, et al. Chemotherapy of advanced esophageal carcinoma: eastern cooperative oncology group experience. Cancer. 1980;46:2149–53.

    Article  CAS  PubMed  Google Scholar 

  5. Akutsu Y, Kono T, Uesato M, et al. S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. Oncology. 2013;84:305–10.

    Article  CAS  PubMed  Google Scholar 

  6. Ito T, Honma Y, Hirano H, et al. S-1 monotherapy after failure of platinum plus 5-fluorouracil chemotherapy in recurrent or metastatic esophageal carcinoma. Anticancer Res. 2019;39:3931–6.

    Article  PubMed  Google Scholar 

  7. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216–20.

    Article  CAS  PubMed  Google Scholar 

  8. Mannell A, Winters Z. Carboplatin in the treatment of oesophageal cancer. S Afr Med J. 1989;76:213–4.

    CAS  PubMed  Google Scholar 

  9. Queisser W, Preusser P, Mross KB, et al. Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of the phase I/II study group of the association for medical oncology of the german cancer society. Onkologie. 1990;13:190–3.

    CAS  PubMed  Google Scholar 

  10. Taguchi T, Wakui A, Nabeya K, et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S gastrointestinal cancer study group. Gan To Kagaku Ryoho. 1992;19:483–8.

    CAS  PubMed  Google Scholar 

  11. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86:1086–91.

    Article  CAS  PubMed  Google Scholar 

  12. Ilson DH, Wadleigh RG, Leichman LP, et al. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007;18:898–902.

    Article  CAS  PubMed  Google Scholar 

  13. Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011a;67:1265–72.

    Article  CAS  PubMed  Google Scholar 

  14. Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol. 1996;13:87–93.

    Article  CAS  PubMed  Google Scholar 

  15. Heath EI, Urba S, Marshall J, et al. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investig New Drugs. 2002;20:95–9.

    Article  CAS  Google Scholar 

  16. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.

    Article  CAS  PubMed  Google Scholar 

  17. Kelsen DP, Bains M, Cvitkovic E, et al. Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep. 1979;63:2019–21.

    CAS  PubMed  Google Scholar 

  18. Bedikian AY, Valdivieso M, Bodey GP, et al. Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemother Pharmacol. 1979;2:263–6.

    Article  CAS  PubMed  Google Scholar 

  19. Bezwoda WR, Derman DP, Weaving A, et al. Treatment of esophageal cancer with vindesine: an open trial. Cancer Treat Rep. 1984;68:783–5.

    CAS  PubMed  Google Scholar 

  20. Conroy T, Etienne PL, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European organization for research and treatment of cancer gastrointestinal treat cancer cooperative group. J Clin Oncol. 1996;14:164–70.

    Article  CAS  PubMed  Google Scholar 

  21. Harstrick A, Bokemeyer C, Preusser P, et al. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol. 1992;29:321–2.

    Article  CAS  PubMed  Google Scholar 

  22. Mühr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, et al. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Color Dis. 2003;18:330–4.

    Article  Google Scholar 

  23. Nanus DM, Kelsen DP, Lipperman R, et al. Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investig New Drugs. 1988;6:239–41.

    Article  CAS  Google Scholar 

  24. Sandler AB, Kindler HL, Einhorn LH, et al. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol. 2000;11:1161–4.

    Article  CAS  PubMed  Google Scholar 

  25. Mannell A, Becker PJ, Melissas J, et al. Intubation vs. dilatation plus bleomycin in the treatment of advanced oesophageal cancer. The results of a prospective randomized trial. S Afr J Surg. 1986;24:15–9.

    CAS  PubMed  Google Scholar 

  26. Engstrom PF, Lavin PT, Klaassen DJ. Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep. 1983;67:713–5.

    CAS  PubMed  Google Scholar 

  27. Panettiere FJ, Leichman LP, Tilchen EJ, et al. Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a southwest oncology group study. Cancer Treat Rep. 1984;68:1023–4.

    CAS  PubMed  Google Scholar 

  28. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247–59.

    Article  CAS  PubMed  Google Scholar 

  29. Coonley CJ, Bains M, Heelan R, et al. Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep. 1983;67:397–8.

    CAS  PubMed  Google Scholar 

  30. Radice PA, Bunn PA Jr, Ihde DC. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin’s lymphomas, and other malignancies. Cancer Treat Rep. 1979;63:1231–9.

    CAS  PubMed  Google Scholar 

  31. Levard H, Pouliquen X, Hay JM, et al. 5-fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French associations for surgical research. Eur J Surg. 1998;164:849–57.

    Article  CAS  PubMed  Google Scholar 

  32. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese esophageal oncology group trial. Jpn J Clin Oncol. 1992;22:172–6.

    CAS  PubMed  Google Scholar 

  33. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG) trial (JCOG9407). Jpn J Clin Oncol. 2001;31:419–23.

    Article  CAS  PubMed  Google Scholar 

  34. Caroli-Bosc FX, Van Laethem JL, Michel P, et al. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. Eur J Cancer. 2001;37:1828–32.

    Article  CAS  PubMed  Google Scholar 

  35. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667–73.

    Article  CAS  PubMed  Google Scholar 

  36. Lee J, Im YH, Cho EY, et al. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharamcol. 2008;62:77–84.

    Article  CAS  Google Scholar 

  37. Conroy T, Etienne PL, Adenis A, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol. 2002;13:721–9.

    Article  CAS  PubMed  Google Scholar 

  38. Kroep JR, Pinedo HM, Giaccone G, et al. Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol. 2004;15:230–5.

    Article  CAS  PubMed  Google Scholar 

  39. Wang J, Chang J, Yu H, et al. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. Cancer Chemother Pharmacol. 2013;71:905–11.

    Article  CAS  PubMed  Google Scholar 

  40. Qin TJ, An GL, Zhao XH, et al. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol. 2009;15:871–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Kato K, Muro K, Ando N, et al. A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan clinical oncology group (JCOG) trial (JCOG 9905-DI). Esophagus. 2014;11(3):183–8.

    Article  CAS  Google Scholar 

  42. El-Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol. 2004;15:960–5.

    Article  CAS  PubMed  Google Scholar 

  43. van der Gaast A, Kok TC, Kerkhofs L, et al. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer. 1999;80:1052–7.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer. 1998;78:511–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhang X, Shen L, Li J, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol. 2008;31:29–33.

    Article  PubMed  Google Scholar 

  46. Shi Y, Qin R, Wang ZK, et al. Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther. 2013;6:585–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Gong Y, Ren L, Zhou L, et al. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol. 2009;64:327–33.

    Article  CAS  PubMed  Google Scholar 

  48. Cao W, Xu C, Lou G, et al. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol. 2009;39:582–7.

    Article  PubMed  Google Scholar 

  49. He YF, Ji CS, Hu B, et al. A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol. 2013;19:5910–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Yun T, Han JY, Lee JS, et al. Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer. 2011;11:385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Shim HJ, Cho SH, Hwang JE, et al. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol. 2010;33:624–8.

    Article  CAS  PubMed  Google Scholar 

  52. Yoshioka T, Sakayori M, Kato S, et al. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol. 2006;11:454–60.

    Article  CAS  PubMed  Google Scholar 

  53. Jin J, Xu X, Wang F, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 2009;4:1017–21.

    Article  PubMed  Google Scholar 

  54. Akutsu Y, Shuto K, Kono T, et al. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepato-Gastroenterology. 2012;59:2095–8.

    CAS  PubMed  Google Scholar 

  55. Kajiura S, Hosokawa A, Yoshita H, et al. Phase I study of docetaxel plus nedaplatin in patients with metastatic or recurrent esophageal squamous cell carcinoma after cisplatin plus 5-fluorouracil treatment. Am J Clin Oncol. 2013;39(1):13–7.

    Article  CAS  Google Scholar 

  56. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826–34.

    Article  CAS  PubMed  Google Scholar 

  57. Takahashi H, Arimura Y, Yamashita K, et al. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 2010;5:122–8.

    Article  PubMed  Google Scholar 

  58. Tanaka Y, Yoshida K, Sanada Y, et al. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010;66:1159–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Osaka Y, Shinohara M, Hoshino S, et al. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res. 2011;31:633–8.

    CAS  PubMed  Google Scholar 

  60. Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80:307–13.

    Article  CAS  PubMed  Google Scholar 

  61. Tamura S, Imano M, Takiuchi H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res. 2012;32:1403–8.

    CAS  PubMed  Google Scholar 

  62. Hironaka S, Tsubosa Y, Mizusawa J, et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014;105:1189–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Guo JF, Zhang B, Wu F, et al. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. Chin J Cancer. 2010;29:321–4.

    Article  PubMed  Google Scholar 

  64. Honda M, Miura A, Izumi Y, et al. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:641–5.

    Article  CAS  PubMed  Google Scholar 

  65. Mauer AM, Kraut EH, Krauss SA, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol. 2005;16:1320–5.

    Article  CAS  PubMed  Google Scholar 

  66. Kanai M, Matsumoto S, Nishimura T, et al. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol. 2007;12:224–7.

    Article  CAS  PubMed  Google Scholar 

  67. Kataoka K, Tsushima T, Mizusawa J, et al. A randomized controlled phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastaticor recurrent esophageal cancer: rationale, design and methods of Japan clinical oncology group study JCOG1314 (MIRACLE study). Jpn J Clin Oncol. 2015;45:494–8.

    Article  PubMed  Google Scholar 

  68. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. JAMA. 1999;281:1623–7.

    Article  CAS  PubMed  Google Scholar 

  69. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.

    Article  CAS  PubMed  Google Scholar 

  70. Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan clinical oncology group study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.

    Article  PubMed  Google Scholar 

  71. Kato K, Igaki H, Ito Y, et al. Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502). J Clin Oncol. 2019a;37(4):7–7.

    Article  Google Scholar 

  72. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011b;81:684–90.

    Article  CAS  PubMed  Google Scholar 

  73. Kato K, Nakajima TE, Ito Y, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013a;43(6):608–15.

    Article  PubMed  Google Scholar 

  74. Ito Y, Takeuchi H, Ogawa G, et al. A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909). J Clin Oncol. 2018;36(15):4051.

    Article  Google Scholar 

  75. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–14.

    Article  CAS  PubMed  Google Scholar 

  76. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.

    Article  PubMed  Google Scholar 

  77. Higuchi K, Koizumi W, Tanabe S, et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol. 2008;87:398–404.

    Article  CAS  PubMed  Google Scholar 

  78. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.

    Article  PubMed  Google Scholar 

  79. Meunier B, Raoul J, Le Prisé E, et al. Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg. 1998;15:224–6.

    Article  CAS  PubMed  Google Scholar 

  80. Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.

    Article  PubMed  Google Scholar 

  81. Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49–54.

    Article  PubMed  Google Scholar 

  82. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391–5.

    Article  CAS  PubMed  Google Scholar 

  83. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.

    Article  PubMed  Google Scholar 

  84. Münch S, Pigorsch SU, Devečka M, et al. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol. 2018;13:139.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.

    Article  CAS  PubMed  Google Scholar 

  86. Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Tsushima T, Mizusawa J, Sudo K, et al. Risk factors for esophageal fistula associated with chemoradiotherapy for locally advanced unresectable esophageal cancer: a supplementary analysis of JCOG0303. Medicine (Baltimore). 2016;95(20):e3699.

    Article  CAS  Google Scholar 

  88. Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus. Jpn J Clin Oncol. 2019;49(11):1055–60.

    Article  PubMed  Google Scholar 

  90. Janmaat ML, Gallegos-Ruiz ML, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol. 2006;24:1612–9.

    Article  CAS  PubMed  Google Scholar 

  91. Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117:1409–14.

    Article  CAS  PubMed  Google Scholar 

  92. Ferry DR, Dutton SJ, Mansoor W, et al. Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib). Ann Oncol. 2012;23:ixe1–ixe30.

    Article  Google Scholar 

  93. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627–37.

    Article  CAS  PubMed  Google Scholar 

  94. Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 2017;3:1520–8.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Kato H, Arao T, Matsumoto K, et al. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013b;42:1151–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Sunpaweravong P, Sunpawervong S, Puttawibul P, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:111–9.

    Article  CAS  PubMed  Google Scholar 

  97. Yang YL, Xu KL, Zhou Y, et al. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. Chin Med J. 2012;125:450–4.

    PubMed  Google Scholar 

  98. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118:1173–80.

    Article  CAS  PubMed  Google Scholar 

  99. Boone J, van Hillegersberg R, Offerhaus GJ, et al. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus. 2009;22:496–504.

    Article  CAS  PubMed  Google Scholar 

  100. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev. 2010;36:235–48.

    Article  CAS  PubMed  Google Scholar 

  101. Petty RD, Dahle-Smith A, Stevenson DAJ, et al. Gefitinib and EGFR gene copy number aberrations in esophageal cancer. J Clin Oncol. 2017;35(20):2279–87.

    Article  CAS  PubMed  Google Scholar 

  102. Moehler MH, Thuss-Patience PC, Brenner B, et al. Cisplatin/5-FU (CF) +/− panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): an open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER). J Clin Oncol. 2017;35(15):4011.

    Article  Google Scholar 

  103. Kojima T, Yamazaki K, Kato K, et al. Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors. Cancer Sci. 2018;109(10):3253–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. de Castro JG, Segalla JG, de Azevedo SJ, et al. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial. Eur J Cancer. 2018;88:21–30.

    Article  CAS  Google Scholar 

  105. Kato K, Ura T, Koizumi W, et al. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: a phase I study. Cancer Sci. 2018;109:785–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Guo W, Wang P, Li N, et al. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget. 2018;9:13920–33.

    Article  PubMed  Google Scholar 

  107. Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631–9.

    Article  CAS  PubMed  Google Scholar 

  108. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to one prior chemotherapy (ATTRACTION-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019b;20(11):1506–17.

    Article  CAS  PubMed  Google Scholar 

  109. Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2018;5(4):546–50.

    Article  PubMed Central  Google Scholar 

  110. Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2019;37(4):2–2.

    Article  Google Scholar 

  111. Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36:61–7.

    Article  CAS  PubMed  Google Scholar 

  112. Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019c;15:1057–66.

    Article  CAS  PubMed  Google Scholar 

  113. Lee DH, Kim HR, Keam B, et al. Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC). J Clin Oncol. 2019;37(4):146.

    Article  Google Scholar 

  114. Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie. 2005;28:281–8.

    CAS  PubMed  Google Scholar 

  115. Möbius C, Freire J, Becker I, et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg. 2007;31:1768–72.

    Article  PubMed  Google Scholar 

  116. Uchida S, Shimada Y, Watanabe G, et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p 53 mutation, advanced stage and poor prognosis. Br J Cancer. 1998;77:1704–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther. 2017;10:3965–9.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Kato K, Doi T, Kojima T, et al. Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). J Clin Oncol. 2017;35(15):4069.

    Article  Google Scholar 

  119. Sawada G, Niida A, Uchi R, et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 2016;150:1171–82.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Center Hospital, Gastrointestinal Medical Oncology, Tokyo, Japan

    Ken Kato

Authors
  1. Ken Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken Kato .

Editor information

Editors and Affiliations

  1. International Goodwill Hospital, Yokohama, Japan

    Nobutoshi Ando

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kato, K. (2020). Chemotherapy and Chemoradiotherapy. In: Ando, N. (eds) Esophageal Squamous Cell Carcinoma. Springer, Singapore. https://doi.org/10.1007/978-981-15-4190-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-4190-2_15

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-4189-6

  • Online ISBN: 978-981-15-4190-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation